International Journal of Radiation Oncology Biology Physics最新文献

Purpose: Primary Hepatocellular Carcinoma (HCC) lesions are frequently treated with fractionated radiation therapy. The linear-quadratic (LQ) model can be used to compare different fractionation schemes for their effect on the local recurrence rate of the HCC tumors. In this paper we seek to find the value of the α/β ratio in the LQ model, which gives the best prediction of the recurrence rate.

Methods and materials: Two separate datasets were analyzed. The first dataset contains the time to recurrence of 390 lesions, treated at two institutions between 2008 and 2021. Factors considered were the Gross Tumor Volume (GTV), the fractionation scheme, the Dose-Volume-Histogram (DVH) of GTV and the elapsed time between the first and last dose of radiation. Four different ways of summarizing the DVH, based on the LQ model, were used and combined with the Cox proportional hazards model to estimate the α/β ratio. The second dataset contains the recurrence rate at 1, 2, 3, 4 and 5 years, for 46 different fractionation schemes, derived from the results presented in 41 publications, based on a total of 4,313 lesions. For this meta-analysis a linear model of a transformed recurrence rate, assuming an autoregressive covariance structure, was used to estimate the α/β ratio.

Results: From the lesion level data the best estimate of α/β was in the range 37.5 to 52 Gy, with a wide confidence interval of (3.4, ∞). A combined model of how the radiation was delivered, based on the fraction regimen and elapsed time, was strongly associated with the hazard of recurrence (p<0.001). However, the elapsed time alone was not significantly associated with the hazard of recurrence (hazard ratio for a 1 day increase = 1.01, p=0.33). The analysis also suggested that larger GTV may lead to a higher hazard of recurrence, but was not statistically significant (hazard ratio of log(GTV)=1.12, p=0.21). Lower doses in the DVH were better predictors of the outcome than the mean DVH dose. The meta analysis of the published data gave the best estimate of α/β ratio of 161.4Gy, but with a wide confidence interval (4.7,∞).

Conclusions: Both analyses suggested a high value of α/β of at least 37.5Gy, but neither could provide precise estimates and only very small values could be excluded. From a practical perspective, any value of the α/β ratio of greater than about 20Gy would give a similar ranking of the merits of different fractionation schemes. To obtain more precise estimates of α/β, the datasets would need to include more patients who received fractionated radiation with doses per fraction in the range of 2.0 to 2.9Gy.

Purpose: Improved communication by clinicians at initial consultation may reduce anxiety and psychological burden of cancer treatment. Based on our pilot qualitative study which involved semi-structured interviews with breast cancer patients, we developed Curietherapy User eXperience (CurieUx), an educational tool integrating augmented reality display technology into radiation oncology consultations.

Methods: We developed an interactive 3-dimensional hologram using an augmented reality desktop display. Animated modules on patient-specific anatomy (breast, regional lymph nodes, organs-at-risk), simulation, linear accelerator, and positioning (prone and breath holding techniques) were created. Patients with newly diagnosed breast cancer undergoing initial radiation oncology consult were prospectively enrolled. Likert scale surveys on anxiety (NIH PROMIS), radiation knowledge, and augmented reality experience (modified IBM technology usability survey) were administered to patients before and after consultation.

Results: A total of 40 newly diagnosed breast cancer patients were enrolled in this proof-of-concept study at a median age of 67 years. Patients reported decreases in multiple components of anxiety after consultation with the CurieUx platform, including in fearfulness (2.13 vs 1.78, p=0.003), uneasiness (2.28 vs. 1.82, p=0.008), nervousness (2.41 vs 2.06, p=0.005), and tenseness (2.28 vs 1.87, p=0.004). Patients reported significant increases in radiation knowledge across multiple domains, including treatment machine (2.35 vs 4.7, p<0.001), radiation (2.7 vs 4.58, p<0.001), positioning (2.49 vs 4.68, P<0.001), and confidence (2.4 vs 4.3, p<0.001). An overwhelming majority of patients had positive experiences (4 or 5 on Likert scale) using the CurieUx hologram display as part of consultation, including its ease of understanding (97%), clarity (93%), comfort (100%), value (97%), and satisfaction (97%).

Conclusion: Curietherapy User eXperience is a valuable educational tool that reduces patient anxiety and promotes radiation knowledge. In this feasibility study, the vast majority of patients found the incorporation of CurieUx into the existing radiation oncology consultation practice to be a valuable addition to the process.